Price Alert

Rani Therapeutics Inc. (RANI)

NASDAQ: RANI · Real-Time Price · USD

0.62

0.07 (13.01%)

At close: Aug 22, 2025, 3:59 PM

0.60

-3.92%

After-hours: Aug 22, 2025, 07:11 PM EDT

Rani Therapeutics Statistics

Share Statistics

Rani Therapeutics has 72.99M shares outstanding. The number of shares has increased by 8.25% in one year.

Shares Outstanding	72.99M
Shares Change (YoY)	8.25%
Shares Change (QoQ)	0.44%
Owned by Institutions (%)	10.19%
Shares Floating	52.67M
Failed to Deliver (FTD) Shares	2,674
FTD / Avg. Volume	0.15%

Short Selling Information

The latest short interest is 980.01K, so 2.25% of the outstanding shares have been sold short.

Short Interest	980.01K
Short % of Shares Out	2.25%
Short % of Float	2.87%
Short Ratio (days to cover)	1

Valuation Ratios

The PE ratio is -1.3 and the forward PE ratio is -0.81. Rani Therapeutics's PEG ratio is 0.06.

PE Ratio	-1.3
Forward PE	-0.81
PS Ratio	37.95
Forward PS	3.7
PB Ratio	19.58
P/FCF Ratio	-1.09
PEG Ratio	0.06

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Rani Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.5, with a Debt / Equity ratio of 14.91.

Current Ratio	1.5
Quick Ratio	1.5
Debt / Equity	14.91
Debt / EBITDA	-0.59
Debt / FCF	-0.83
Interest Coverage	-10.59

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$9.79K
Profits Per Employee	$-285.89K
Employee Count	105
Asset Turnover	0.03
Inventory Turnover	n/a

Taxes

Income Tax	26.57M
Effective Tax Rate	-88.5%

Stock Price Statistics

The stock price has increased by -82.08% in the last 52 weeks. The beta is -0.01, so Rani Therapeutics's price volatility has been lower than the market average.

Beta	-0.01
52-Week Price Change	-82.08%
50-Day Moving Average	0.53
200-Day Moving Average	1.19
Relative Strength Index (RSI)	52.47
Average Volume (20 Days)	1,832,014

Income Statement

In the last 12 months, Rani Therapeutics had revenue of 1.03M and earned -30.02M in profits. Earnings per share was -1.05.

Revenue	1.03M
Gross Profit	1.03M
Operating Income	-53.31M
Net Income	-30.02M
EBITDA	-50.52M
EBIT	-51.55M
Earnings Per Share (EPS)	-1.05

Full Income Statement

Balance Sheet

The company has 3.76M in cash and 29.71M in debt, giving a net cash position of -25.95M.

Cash & Cash Equivalents	3.76M
Total Debt	29.71M
Net Cash	-25.95M
Retained Earnings	-102.91M
Total Assets	16.9M
Working Capital	-9.55M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -35.5M and capital expenditures -268K, giving a free cash flow of -35.76M.

Operating Cash Flow	-35.5M
Capital Expenditures	-268K
Free Cash Flow	-35.76M
FCF Per Share	-1.26

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -5186.19% and -2920.04%.

Gross Margin	100%
Operating Margin	-5186.19%
Pretax Margin	-2920.04%
Profit Margin	-2920.04%
EBITDA Margin	-4914.69%
EBIT Margin	-5186.19%
FCF Margin	-3478.99%

Dividends & Yields

RANI does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for RANI is $9, which is 1536.4% higher than the current price. The consensus rating is "Buy".

Price Target	$9
Price Target Difference	1536.4%
Analyst Consensus	Buy
Analyst Count	3

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-18.89
Piotroski F-Score	1